Metraipolis › archive › dc_f482cf5dec1a

Real-World Effectiveness of Polymerized House-Dust-Mite Subcutaneous Immunotherapy up to 24 Months: Why Baseline Symptom Severity Shapes Measurement of the… — Europe PMC PMID:42652786

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42652786
DOI
10.3390/jcm15166383
License (as archived)
solo-consultazione
Archived
2026-10-08T03:14:13.981Z
SHA-256 of the archived text
8a025e40299b5d8ddb42d9cccd5259f47d30f262ca1161caa7222b58646af7ee
Stable URL of this page
https://metraipolis.com/documento/dc_f482cf5dec1a

How to cite

Real-World Effectiveness of Polymerized House-Dust-Mite Subcutaneous Immunotherapy up to 24 Months: Why Baseline Symptom Severity Shapes Measurement of the… — Europe PMC PMID:42652786 — Europe PMC (en), https://europepmc.org/article/MED/42652786 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f482cf5dec1a (Metraipolis archive dc_f482cf5dec1a, sha256 8a025e40299b5d8ddb42d9cccd5259f47d30f262ca1161caa7222b58646af7ee)
BibTeX
@misc{dcf482cf5dec1a,
  title = {Real-World Effectiveness of Polymerized House-Dust-Mite Subcutaneous Immunotherapy up to 24 Months: Why Baseline Symptom Severity Shapes Measurement of the… — Europe PMC PMID:42652786},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42652786},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f482cf5dec1a; sha256 8a025e40299b5d8ddb42d9cccd5259f47d30f262ca1161caa7222b58646af7ee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42652786. Agents can read the archived copy with the MCP tool read_document.